ArticleFrontiers in neurology
Development and internal validation of an inflammation-platelet synergy score for anterior circulation cerebral infarction: an exploratory case-control study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory and thrombotic pathways interact in atherothrombotic stroke pathogenesis, yet combined assessment of these markers for distinguishing patients with anterior circulation cerebral infarction from high-risk controls remains underexplored. We aimed to develop and internally validate an inflammation-platelet synergy score in an exploratory case-control framework. Methods: This retrospective case-control study enrolled 203 patients with anterior circulation cerebral infarction and 98 high-risk controls with carotid atherosclerosis from January 2018 to June 2024. The synergy score incorporated six parameters: C-reactive protein (CRP), mean platelet volume (MPV), platelet distribution width (PDW), platelet count, intima-media thickness (IMT), and unstable plaque status. Discriminative performance was assessed using receiver operating characteristic analysis with bootstrap internal validation. Decision curve analysis was performed to evaluate potential clinical utility. Risk stratification was evaluated across low-risk (0-2 points), intermediate-risk (3-4 points), and high-risk (5-7 points) categories. Results: Cases exhibited significantly elevated CRP (median 6.2 vs. 3.5 mg/L, Conclusion: In this exploratory case-control study, the inflammation-platelet synergy score demonstrated good discriminative ability for anterior circulation cerebral infarction using routinely available parameters. These preliminary findings require prospective validation with pre-event biomarker measurement before any clinical application can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.